Drug industry

Article Abstract:

Drug company earnings in the 3rd qtr of 1995 are above, or in line with, industry expectations. Takeover speculation and sector rotation are both benefitting the industry. Further industry consolidation may inflate drug stock prices, but only three of 28 listed drug company stocks declined in the 3rd qtr of 1995. Investors need to closely monitor stocks on an individual basis before purchase of these shares.

Pharmaceutical Preparation Manufacturing, Pharmaceutical preparations, Economic aspects, Drugs, Finance, Eli Lilly and Co., Pfizer Inc., Glaxo Wellcome PLC, SmithKline Beecham Corp. (Philadelphia, Pennsylvania), SBH, Genentech Inc., Biogen Inc., Bristol-Myers Squibb Co., ALZA Corp., Amgen Inc., Chiron Corp., Forest Laboratories Inc., Genzyme Corp., Immunex Corp., IVAX Corp., Mylan Laboratories Inc., Perrigo Co., Schering-Plough Corp., Sicor Inc., AZA, AHP, AMGN, BGEN, BMY, CHIR, CYGN, FRX, GENZ, ICN, IMNX, IVX, LLY, MLY, PRGO, SGP, Genetics Institute Inc., GENI, GNE, Valeant Pharmaceuticals International, Wyeth, Merck & Company Inc., Rhone-Poulenc Rorer Inc., Cygnus Therapeutic Systems, Roberts Pharmaceutical Corp., RPCX, R.P. Scherer Corp., RPR, GNSA, SHR, WLAX

---

Novartis AG

Article Abstract:

The shares of Novartis AG have decent price appreciation potential over the 2010-2012 timeframe. The Swiss company offers a variety of pharmaceutical and health care products such as vaccines and generics.

Evaluation, Novartis AG, Securities, Stock prices

---

Similar abstracts:

• Abstracts: Drug industry. Myriad Genetics. Amgen
• Abstracts: Power industry. Hess Corp
• Abstracts: Apparel industry. Iconix Brand Grp
• Abstracts: Paper & forest products industry. part 5

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.